Category: Press Releases

Growing CLIA System Installations to Drive Reagent and Consumables Revenue, Supporting Long-Term Business Growth

Hsinchu, Taiwan — August 10, 2026

General Biologicals Corporation (GBC, hereinafter referred to as “GBC”; TWSE: 4117), a precision healthcare solutions provider, today announced consolidated revenue of NT$24.63 million for July 2026, representing a 57.82% year-on-year increase. The growth was primarily driven by continued growth in orders for its precision healthcare testing business. Some overseas reagent orders have been rescheduled by customers and will be recognized progressively from August. This adjustment does not affect overall order momentum or the Company’s full-year operating outlook. Consolidated revenue for January through July 2026 totaled NT$179.85 million, up 41.77% from the same period last year.

GBC stated that its CLIA Chemiluminescence Immunoassay System is expected to be one of the key growth drivers of its precision healthcare business. The CLIA platform has gradually been introduced into healthcare institutions and laboratories in Taiwan. Its business model leverages instrument placements to generate continued demand for reagents and consumables. Each additional system installed is expected to create long-term testing demand and recurring revenue opportunities. Currently, approximately 11 systems have been installed at healthcare institutions and laboratories in Taiwan. As the installed base continues to expand, the commercial benefits of the CLIA platform are expected to become increasingly evident.

GBC further stated that its CLIA Chemiluminescence Immunoassay System offers high efficiency, high throughput, and high sensitivity, supporting a wide range of testing applications, including tumor markers, thyroid function, hormones, and infectious diseases. More than 10 chemiluminescence reagent assays have obtained TFDA medical device approvals, while the Company continues to develop additional reagent products and pursue regulatory certifications.

As the medical testing market gradually shifts from individual testing toward automated and platform-based solutions and long-term health management, demand for automated testing systems, reagents, and consumables from healthcare institutions and laboratories is also increasing. This trend is expected to support GBC’s long-term growth through its “system placement + reagents and consumables” business model.

Looking ahead to the third quarter of 2026, GBC will focus on its development strategy of “proprietary instrument development + reagents and consumables + testing services + overseas regional distribution partnerships.” The Company will accelerate regulatory approvals and overseas market expansion for its CLIA Chemiluminescence Immunoassay System. In addition, continued sales growth from “oh care,” the proprietary brand of GBC’s subsidiary Gene Research Laboratories Co., Ltd. (GRL), is expected to contribute positively to future operating performance.

For the second half of 2026, GBC will continue to expand CLIA system installations, broaden its chemiluminescence reagent portfolio, increase utilization among existing healthcare institutions, and accelerate overseas market expansion. These efforts are expected to progressively enhance the commercial value of the CLIA platform and lay a solid foundation for future business growth.

In addition, continued growth in sales of “oh care,” together with ongoing development in AI-assisted interpretation, digital pathology, and precision healthcare solutions, will enable GBC to further strengthen its integrated precision healthcare offerings and long-term competitive advantages, supporting sustainable business growth.

GBC Consolidated Revenue Summary for July 2026

Unit: NT$ thousand; %

Period	2026	2025	YoY %
July	24,625	15,603	57.82
January–July	179,845	126,856	41.77

Media Contacts

General Biologicals Corporation (GBC)
M. D. Lin, General Manager
Tel: +886-3-577-9221
frank.lin@gbc.com.tw

IR Trust
Sandy Cheng, Vice President
Tel: +886-2-2585-5701 / +886-931-914-467
sandy@ir-trust.tw

About GBC

General Biologicals Corporation (GBC; TWSE: 4117) was founded in June 1984 and has established an integrated value chain covering research, development, manufacturing, sales, and testing services. For more than 40 years, GBC has remained committed to its goal of creating better and more affordable in-vitro diagnostic (IVD) products that are accessible to everyone.

Its product portfolio covers infectious diseases, respiratory infections, blood virology, fertility and sexual health, oncology, human genetics, and emerging infectious diseases. GBC’s IVD products and instruments have become trusted solutions for healthcare professionals, laboratory technicians, blood banks, and consumers worldwide, with products currently sold in more than 40 countries.

Building on its expertise in testing, GBC is committed to integrating testing with other healthcare approaches and expanding into precision healthcare, preventive healthcare, and broader health management. Its business areas include precision IVD reagents, Digital Medical Laboratory (DML) services, antimicrobial peptide (AMP) pharmaceuticals, and healthcare product commercialization. Through a diversified business model, GBC is building a long-term presence in the broader healthcare sector.

GBC Official Website: https://www.gbc.com.tw/tw/home/

Disclaimer

This document and the related information released concurrently contain forward-looking statements. Except for statements relating to facts that have already occurred, all statements concerning GBC’s future business operations, potential events, and prospects, including but not limited to forecasts, targets, estimates, and operating plans, constitute forward-looking statements.

Forward-looking statements are subject to various factors and uncertainties that may cause actual results to differ materially from those expressed or implied herein. These factors include, but are not limited to, price fluctuations, actual demand, exchange-rate movements, market share, market competition, changes in legal, financial, and regulatory frameworks, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the Company’s control.

These forward-looking statements are based on current expectations and assessments. The Company assumes no obligation to update or revise such statements in the future.

Precision Healthcare and oh care Drive Growth as June Revenue Reaches NT$50.9 Million, Highest in More Than Four Years

Hsinchu, Taiwan — July 14, 2026

General Biologicals Corporation (GBC; TWSE: 4117), a provider of precision healthcare and testing solutions, recently participated in World Health Expo Bangkok 2026 (WHX Bangkok 2026), where it showcased its next-generation CLIA Chemiluminescence Immunoassay System, AIO Fully Automated Nucleic Acid Testing and Analysis System, and a range of testing instruments and reagents.

GBC stated that its participation was aimed at strengthening its presence in the ASEAN market. By showcasing high-throughput and fully automated precision healthcare solutions, GBC expects to further expand and deepen business cooperation opportunities with distributors, healthcare institutions, and large-scale laboratories in Thailand, Malaysia, and other Southeast Asian markets, creating new momentum for the Group’s overseas operations.

GBC noted that as global demand for healthcare, preventive medicine, and precision healthcare continues to grow, the medical testing market is gradually shifting from one-time health checkups and individual tests toward early cancer screening, chronic disease risk monitoring, long-term health management, and automated testing at healthcare institutions. As demand increases for highly efficient, sensitive, automated, and scalable testing platforms, favorable opportunities are emerging for the continued expansion and development of GBC’s precision healthcare business.

At the exhibition, GBC highlighted its CLIA Chemiluminescence Immunoassay Platform, which offers high efficiency, high throughput, and high sensitivity and supports a wide range of testing applications, including tumor markers, thyroid function, hormones, and infectious diseases. GBC has developed 81 chemiluminescence reagent assays, five of which have obtained TFDA medical device approvals. The Company has also established collaborations with three laboratories in Taiwan and is actively planning additional TFDA submissions and EU IVDR certification this year. These efforts are expected to further expand the commercial opportunities for GBC’s products in healthcare institutions and overseas markets.

In the field of molecular testing, GBC’s AIO Fully Automated Nucleic Acid Testing and Analysis System was another key highlight of the exhibition. The platform integrates nucleic acid extraction, PCR setup, real-time quantitative PCR testing, and data analysis into a streamlined workflow. It helps reduce manual operations, shorten testing time, and improve laboratory efficiency, making it suitable for regional hospitals, clinics, and clinical and research laboratories. As demand for molecular testing expands beyond pandemic-related testing to infectious diseases, genetic testing, and precision healthcare applications, the AIO platform is positioned to capture the growing trend toward automated testing workflows.

GBC’s consolidated revenue for June 2026 reached NT$50.9 million, representing a substantial 97.71% month-on-month increase and a 4.43-fold year-on-year increase. This marked the Company’s highest monthly revenue since May 2022, primarily driven by the steady expansion of its precision healthcare business. In addition, sales of “oh care,” the proprietary brand of GBC’s subsidiary Gene Research Laboratories Co., Ltd. (GRL), continued to grow, further contributing to June revenue and setting a new monthly record since May 2022. Consolidated revenue for the first half of 2026 totaled NT$155 million, up 39.52% from the same period last year.

GBC stated that it has actively expanded overseas sales and distribution partnerships in recent years, with sales achievements accumulated across Europe, North America, Brazil, India, Malaysia, the Middle East, and other markets. GBC is particularly optimistic about Southeast Asia, where demographic trends, upgrades in healthcare infrastructure, and growing awareness of health management are expected to support continued growth in demand for testing products. The Group will continue to increase its overseas market penetration through a product strategy centered on automation, platform-based solutions, and the recurring value generated by reagents and consumables.

Looking ahead, GBC will continue advancing the commercialization of its core platforms, including the CLIA Chemiluminescence System, AIO Fully Automated Nucleic Acid Testing and Analysis System, and CellBio Circulating Tumor Cell (CTC) Detection System. At the same time, the Company will accelerate the development of reagent and consumable products, regulatory submissions, and overseas channel partnerships.

As global demand for precision healthcare, early cancer screening, chronic disease monitoring, and automated medical testing continues to expand, GBC will leverage its business model of “proprietary instrument development + reagents and consumables + testing services + channel partnerships” to create sustainable growth momentum for the Group’s medium- and long-term operations.

Media Contacts

General Biologicals Corporation (GBC)
M. D. Lin, General Manager
Tel: +886-3-577-9221
frank.lin@gbc.com.tw

IR Trust
Sandy Cheng, Vice President
Tel: +886-2-2585-5701 / +886-931-914-467
sandy@ir-trust.tw

About GBC

General Biologicals Corporation (GBC; TWSE: 4117) was founded in June 1984 and has established an integrated value chain covering research, development, manufacturing, sales, and testing services. For more than 40 years, GBC has remained committed to its goal of creating better and more affordable in-vitro diagnostic (IVD) products that are accessible to everyone.

Its product portfolio covers infectious diseases, respiratory infections, blood virology, fertility and sexual health, oncology, human genetics, and emerging infectious diseases. GBC’s IVD products and instruments have become trusted solutions for healthcare professionals, laboratory technicians, blood banks, and consumers worldwide, with products currently sold in more than 40 countries.

Building on its expertise in testing, GBC is committed to integrating testing with other healthcare approaches and expanding into precision healthcare, preventive healthcare, and broader health management. Its business areas include precision IVD reagents, Digital Medical Laboratory (DML) services, antimicrobial peptide (AMP) pharmaceuticals, and the commercialization of healthcare and wellness products. Through a diversified business model, GBC is building a long-term presence in the broader healthcare sector.

GBC Official Website:
https://www.gbc.com.tw/tw/home/

Disclaimer

This document and the related information released concurrently contain forward-looking statements. Except for statements relating to facts that have already occurred, all statements concerning GBC’s future business operations, potential events, and prospects, including but not limited to forecasts, targets, estimates, and operating plans, constitute forward-looking statements.

Forward-looking statements are subject to various factors and uncertainties that may cause actual results to differ materially from those expressed or implied herein. These factors include, but are not limited to, price fluctuations, actual demand, exchange-rate movements, market share, market competition, changes in legal, financial, and regulatory frameworks, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the Company’s control.

These forward-looking statements are based on current expectations and assessments. The Company assumes no obligation to update or revise such statements in the future.

Hsinchu County, Taiwan – May 21, 2025 –

General Biologicals Corporation (GBC, TWSE: 4117), a global leader in precision diagnostics and biotech innovation, celebrated the grand opening of its new GBC Biotech Building located in the AI Smart Park, Hsinchu County. The event was presided over by GBC Chairman Mr. TC Lin and attended by distinguished guests from the government, academia, and industry.

The new facility showcases GBC’s commitment to advancing the future of healthcare through AI integration, green building principles, and modular design. Chairman Lin emphasized the company’s core values—Truth, Goodness, and Beauty—as reflected in the building’s architecture. These principles embody cutting-edge AI systems for diagnostics, environmentally conscious construction that improves indoor air quality, and sustainable practices aligned with ESG goals.

Establishing Taiwan’s AI-Powered Diagnostic Hub

The Zhubei Biotech Building will serve as GBC’s global hub for:

• AI-driven circulating tumor cell (CTC) big data production and digital pathology laboratories
• Macrocyclic peptide drug development and manufacturing
• International CDMO (contract development and manufacturing) services

This strategic expansion enables localized production and professional diagnostic services to meet growing global demand—reinforcing GBC’s vision for a healthier Taiwan and a healthier world.

Strengthening Innovation in Precision Medicine

GBC continues to enhance its CellBio™ liquid biopsy platform, integrating AI-assisted image recognition technology with digital fluorescence scanning. This allows for efficient CTC image acquisition, storage, and AI-based analysis—empowering physicians with precise cancer diagnostics and treatment monitoring tools.

As of April 2025, GBC’s business is segmented as follows:

• Precision Medicine: 64% of total revenue
• Digital Medical Healthcare Services: 17%
• Biopharmaceuticals and Health Products: 19%

GBC’s business model focuses on combining diagnostic devices with reagents to support hospitals, clinics, and laboratories globally. The company’s chemiluminescent immunoassay (CLIA) systems have secured orders from Taiwan with ongoing expansion into the Middle East and Southeast Asia.

Expanding Product and Market Reach

The CLIA platform supports diverse applications including tumor markers, thyroid function, infectious diseases, hormones, cytokines, and cardiac biomarkers. GBC is actively pursuing TFDA approval for its CLIA instruments and reagent kits, with scalable systems designed to serve both high- and low-throughput environments.

GBC’s full-service model—from R&D and production to global distribution and clinical diagnostics—positions the company as a key innovator in the IVD industry. The company aims to expand its presence in major hospitals in Taiwan, strengthen international partnerships, and advance its portfolio in biologics and personalized healthcare solutions.
 

 

About General Biologicals Corporation (GBC)

Founded in 1984, GBC is a publicly listed company (TWSE: 4117) with a fully integrated business spanning research, product development, manufacturing, and diagnostic services. GBC provides trusted IVD solutions to hospitals, labs, and blood banks across more than 40 countries. Its portfolio includes infectious diseases, oncology, reproductive health, and personalized diagnostics. Through its diversified business model and innovation in liquid biopsy, digital health, and antimicrobial peptide therapies, GBC is driving the next generation of health technologies.

 

Media Contact

Frank Lin, President

✉️ info@gbc.com.tw

 

Jan.16, 2025, Taipei

Precision medicine leader GBC announced that its General Manager, Mr. Frank Lin, was invited to attend the SNQ (Symbol of National Quality) Award Ceremony today. The company’s fully automated CellBio™ FX10 system was recognized in the “Precision Testing Group” under the “Medical Peripheral Services and Products” category for the 2024 SNQ Awards. This recognition not only affirms the excellence of the CellBio™ FX10 system but also highlights GBC’s strong R&D capabilities and competitive edge, further supporting the expansion of its liquid biopsy business opportunities.

The SNQ certification is established by the Institute for Biotechnology and Medicine Industry (IBMI), aimed at advancing the quality and internationalization of Taiwan’s biotechnology and medical industries. The symbol represents not only safety and quality but also excellence in product and service performance. GBC’s receipt of this prestigious recognition reflects its commitment to the principle of “Precision Medicine and Innovative Development.” The company adheres to stringent quality management standards in the design and development of medical products while actively expanding its three major business domains: precision medicine, digital medical diagnostics, and the development of new drugs and bio-nutraceuticals.

General Manager Mr. Frank Lin highlighted that the company’s fully automated CellBio™ circulating tumor cell (CTC) detection system has received numerous accolades, including the SNQ certification, Taiwan Excellence Award, and National Innovation Excellence Award. This detection system leverages a non-invasive sampling process to quickly and effectively capture circulating tumor cells (CTCs) from blood samples. With just a small 7.5 mL blood draw, it can accurately monitor CTC counts in the bloodstream, boasting over 90% cancer cell capture efficiency. It provides a highly precise and efficient screening method, helping patients receive optimal medical care, enabling early cancer detection, postoperative recurrence monitoring, and treatment efficacy evaluation—setting new standards in cancer diagnostics and post-operative treatment guidance.

Furthermore, GBC continues to deepen its CTC monitoring services (CellBio™) through close collaborations with hospitals and clinics. The company has also forged cross-industry partnerships, such as an alliance with Fubon Life Insurance, offering policyholders health examination services like “Circulating Tumor Cell (CTC) Testing” and “Tumor Marker Testing.” These efforts further solidify GBC’s long-term operational growth.

Looking ahead, GBC anticipates sustained growth in demand for precision medical diagnostics and liquid biopsy markets. The company is actively strengthening its five core business areas: precision diagnostics, liquid biopsy, CDMO, diagnostic services, and P113 Antimicrobial Peptide pharmaceuticals. To optimize resource integration, GBC’s AI Campus Headquarters is expected to be operational in the second half of this year. It will support the development of nine specialized centers, including a Molecular Diagnostics Laboratory, Diagnostic Instrument Innovation R&D Center, Precision Medical Diagnostics Center, Immune and Stem Cell Culture Center, Protein Drug R&D and Pilot Production Center, and Personalized Smart Precision Medical Services Center, positioning itself for the growing global demand for precision healthcare solutions.

GBC (4117) announced today (4th) that it continues to deepen its focus in areas such as precision diagnostics, liquid biopsy, CDMO testing services, and P113 antimicrobial peptide drug products. These efforts aim to expand the group’s service scope and align with the trends in precision health. GBC will showcase its products, including the Chemiluminescence Analyzer (CLIA), the GBC AIO M160 fully automated nucleic acid detection system, and the CellBio Circulating Tumor Cell (CTC) detection system, at the 2024 Taiwan Healthcare+ Expo from December 5 to December 8.

Notably, the GBC CL i120 Chemiluminescence Analyzer (CLIA) under GBC has officially received special project manufacturing approval from Taiwan’s TFDA in Q4 and is concurrently progressing in its application for EU IVDR medical device certification. This development is expected to generate robust demand for diagnostic reagent products and support steady growth in GBC precision medicine business.

GBC highlighted its end-to-end operational model, encompassing research and development, manufacturing, clinical trials, and international distribution. This integrated approach strengthens its three major business groups: precision medicine, digital medical diagnostic services, and new drug and biopharmaceutical product development.

In the precision medicine segment, GBC has been actively investing in diagnostic equipment development over the past two years to offer a combined “equipment + diagnostic reagent products” sales service for hospitals, clinics, and laboratories. The GBC CL i120 Chemiluminescence Analyzer has obtained TFDA approval and is pursuing EU IVDR certification, enhancing its opportunities for domestic and international orders. The anticipated increase in equipment sales is expected to drive steady demand for diagnostic reagents, bolstering business growth.

GBC further elaborated on its Chemiluminescence Immunoassay (CLIA) technology platform, which can be used for detecting various conditions such as tumor markers, thyroid function, infectious diseases, hormones, cytokines, cardiovascular conditions, and other specialized applications. Combined with the high-throughput and low-throughput automated CLIA systems (GBC Chemiluminescence Analyzer), these platforms offer features such as high efficiency, precision, smart convenience, flexibility, and reliability. The systems boast testing speeds of 120 to 200 tests per hour, effectively addressing the high-efficiency diagnostic needs of clinical laboratories.

Additionally, GBC introduced its GBC AIO M160, a new fully automated nucleic acid detection analysis system. This molecular diagnostic platform integrates DNA/RNA extraction, amplification, and data analysis functions into a single device. The system supports up to 16 sample tests within 1-2 hours, allowing for direct processing of collected samples while minimizing the risk of cross-contamination. These attributes make it a precise and reliable solution for molecular diagnostics. GBC actively participates in prominent domestic and international biomedical exhibitions to promote its products and foster distributor partnerships.

GBC General Manager, Frank Lin, emphasized the value of precision medicine in providing accurate treatment and tailored therapies while tracking patients’ responses to treatment. He noted the immense potential in diagnostics and pharmaceuticals, particularly given cancer’s status as the leading cause of death in Taiwan. GBC CellBio Circulating Tumor Cell (CTC) detection system features high capture rates and detection precision. In collaboration with Fubon Life Insurance, the company offers “next generation myCTC circulating tumor cell blood testing” services at over 70 blood collection sites. Customers receive test reports within seven working days after sample collection. Since the service’s inception in 2021, testing cases have grown rapidly, with over 25,000 cases accumulated to date, highlighting GBC’ solid footing in precision medicine.

Looking ahead, GBC is committed to advancing its three major business groups, investing in molecular diagnostics, liquid biopsy, and cancer diagnostic technologies. The company also integrates big data and AI technologies to drive biomedical industry upgrades. Furthermore, GBC is set to enhance its resource integration with the expected launch of its AI Park Office Building in the first half of next year. The company plans to establish nine key centers, including a molecular diagnostics laboratory, innovative diagnostic instrument R&D center, precision medical diagnostics center, immune and stem cell cultivation center, protein-based drug R&D and pilot production center, and a personalized precision medicine service center, aligning with the precision health trend.

 

November 27, 2024, Hsinchu
GBC Corporation (referred to as “GBC,” stock code: 4117), a leader in precision medicine, has been honored with the 33rd “2024 Taiwan Excellence Award” for its fully automated CellBio™ Circulating Tumor Cell (CTC) Detection System. Recognized for its high precision, efficiency, and non-invasive approach, the product is revolutionizing early cancer detection and monitoring, making a profound impact on global cancer screening practices. This accolade underscores GBC’s outstanding R&D and manufacturing capabilities in the field of precision medicine.

The CellBio™ Circulating Tumor Cell (CTC) Detection System excels with high capture rates and detection precision for cancer cells. It can process up to 10 samples simultaneously, significantly reducing detection time and minimizing manual intervention. By extracting only 7.5 milliliters of blood, the system effectively isolates and captures rare cancer cells in a non-invasive manner, accurately identifying the number of cancer cells in the blood and monitoring their dynamic changes. With a cancer cell capture rate exceeding 90%, this innovation provides a more reliable solution for early cancer screening. It also assists doctors in health monitoring during treatment, particularly in tracking the effectiveness of treatments and the risk of recurrence for known cancer patients, offering accurate and intuitive data for enhanced medical care.

In its commitment to expanding Taiwan’s cancer screening market, GBC has signed an exclusive agreement with Fubon Life Insurance to offer the “Next-Generation myCTC Blood Circulating Tumor Cell Detection” service to new policyholders. As of October 2024, over 25,000 cases have been completed under this collaboration. GBC continues to deepen its partnership with Fubon and plans to introduce new products while actively seeking collaboration opportunities with hospitals and clinics across Taiwan. These efforts are expected to positively contribute to the company’s future operations.

Looking ahead, GBC is optimistic about the growing market demand for precision medical diagnostics and liquid biopsies. The company is focused on advancing its five core business areas: precision diagnostics, liquid biopsy, CDMO (Contract Development and Manufacturing Organization), diagnostic services, and P113 antimicrobial peptide pharmaceuticals. Leveraging its comprehensive supply chain that spans R&D, manufacturing, sales, and diagnostic services, GBC is steadfast in its mission to “start with diagnostics and collaborate with healthcare partners to protect public health.” The company continues to invest in molecular diagnostics and cancer-related liquid biopsy technologies, aiming to expand its service portfolio and align with the global trend toward precision health.

GBC (4117) announced on the 2nd that it has signed a three-year exclusive distribution agreement with a Brazilian distributor to expand into South America. The main products to be sold include ELISA serum antibody assays, hepatitis A/B/C/D testing assays, as well as CLIA chemiluminescence immunoassay and PCR equipment and related reagents. The Brazilian distributor has already partnered with over 40% of local blood centers, accumulating sales channels with more than 200 laboratories and hospitals. Deliveries are expected to gradually commence from April, boosting GBC’s new growth momentum.

GBC indicated that its revenue distribution for the first two months of this year was 42% in Taiwan, 13% in the Middle East, and 2% in Southeast Asia. Additionally, besides existing sales in Mexico, this collaboration with the Brazilian distributor is expected to generate sales momentum for GBC’s precise testing equipment and reagents, further expanding the company’s sales footprint in South America and enhancing its overall international sales strategy.

Leveraging the group’s integrated operations encompassing research and development, manufacturing, clinical trials, and global distribution, GBC aims to complete and launch its AI park facility in Zhubei in the second half of 2024. Continual negotiations with international distributors will also contribute to expanding the operational scale of precise testing and liquid biopsy services, complementing resources with its existing Zhubei factory in the Hsinchu Science Park and bolstering opportunities for international business development.

Looking ahead, GBC is optimistic about the increasing market demand in precision medical testing and liquid biopsy fields, actively enhancing its core business areas including precise testing, liquid biopsy, CDMO (Contract Development and Manufacturing Organization), testing services, and P113 antimicrobial peptide drugs. Participation in key international biotechnology and medical exhibitions will further raise the visibility of the GBC brand and promote order intake for precise testing and liquid biopsy services, thereby creating favorable growth prospects for GBC’s future operations.

November 21, 2023, Hsinchu, 

Precise Medical Manufacturer GBC Co., Ltd. (referred to as “GBC” with stock code: 4117) was nominated for the 112th National Pharmaceutical Technology & Research Development Awards jointly hosted by Taiwan’s Food and Drug Administration of the Ministry of Health and Welfare and the Industrial Development Bureau of the Ministry of Economic Affairs for its CellBio™technology platform product. Today, at the award ceremony, GBC was honored to receive the “Bronze Award in the Medical Devices Category,” highlighting the company’s continuous enhancement of research and development capabilities and competitive advantages over the years. Alongside its commitment to improving the entire supply chain encompassing research, development, manufacturing, sales, and inspection services, GBC aims to establish a cornerstone for sustained development within the group.

The “National Pharmaceutical Technology & Research Development Awards” is a national-level recognition program categorized into three main sections based on the nature of the research and development products: pharmaceuticals, medical devices, and manufacturing technology. It aims to reward companies that have made outstanding contributions to the research and development of new drugs and related manufacturing technologies. This initiative encourages more companies to showcase their technological advancements in emerging pharmaceuticals or medical devices, thereby elevating Taiwan’s pharmaceutical manufacturing industry standards and clinical trial quality.

 

With GBC’s establishment as a professional testing reagent manufacturing service company contributing to the government’s ten-year plan for hepatitis prevention and control, it has continuously enhanced its team’s research capabilities and competitive advantages over the years. This effort has facilitated the group’s standout performance among numerous high-quality enterprises, resulting in the recognition and awarding of the “Bronze Award in the Medical Devices Category” as a testament to GBC’s contributions.

 

Mr. Frank Lin, President of GBC stated that the group’s proprietary iFiltration™ technology has not only secured patents in Taiwan but has also obtained novel patents in Japan, China, and other countries. Leveraging the microfiltration membrane separation technique of iFiltration™, it effectively isolates cells, achieving a recovery rate of over 97% for circulating tumor cells (CTCs). This technology serves as the core for GBC’s award-winning manual blood cell counting device, a part of the CellBio™ technology platform. The said product requires only a 7.5mL blood sample and can capture CTCs within two hours, enabling the detection of circulating tumor cells in the blood, monitoring dynamic changes in cancer cells within the body. This serves the purpose of early cancer detection, postoperative recurrence monitoring, and tracking treatment effectiveness. It offers a more precise and efficient screening method, aiding patients in receiving more accurate medical care.

 

Looking ahead, GBC will continue to develop comprehensive diagnostic services by actively investing in research and development of related technologies such as molecular diagnostics, liquid biopsies, cancer diagnostics, and more. The company aims to enhance its five core business areas: precision testing, liquid biopsies, CDMO, testing services, and P113 antimicrobial peptide drugs.

 

Moreover, GBC is planning to construct a large-scale office building in the Hsinchu AI Intelligent Park in Zhubei, featuring nine centers focusing on energy conservation, carbon reduction, and establishing a presence in the broader health sector. This project is expected to be completed and operational by the latter half of 2024. The goal is to complement the existing Zhubei factory located in the Hsinchu Science Park, integrating resources to optimize the layout in the field of comprehensive health. This strategic move aims to assist GBC in expanding its international market and business development opportunities.

 

 

 

GBC introduces two CellBio CTC cancer detection devices at AACC
GBC introduces GB RealQuant AIO Sample-To-Results automated molecular system at AACC

HSINCHU, Taiwan – July 24, 2023 – Taiwanese IVD (In-Vitro Diagnostic) manufacturer General Biologicals Corporation (GBC) today unveiled two CellBio™ circulating tumor cell (CTC) cancer detection products at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo, being held July 23-27 in Anaheim, California.

GBC is officially launching its award-winning brand in the U.S. market with a highly competitive niche IVD (in vitro diagnostics) device and assay.

GBC’s two CTC detection systems are viewed globally at the forefront of science and are used for early detection, treatment validation and therapy monitoring with rapid, accessible and affordable diagnostic solutions. The CellBio platform, which uses GBC proprietary iFiltration™ technology, provides positive control, is designed to ensure the filtration efficiency is accurate, and has led to Taiwan’s first standardized CTC system. The technology is patented and won the 2022 Taiwan National Innovation Award.

“CellBio focuses on the detection, monitoring and treatment of cancer metastasis. The goal of GBC is to revolutionize the detection and treatment of cancer through its unique CTC technology and complementary therapeutics platform CellBio,” said Frank Lin, the President of GBC. “More than 10 million patients die from cancer each year and more than 90 percent of the deaths are attributed to metastasis. Currently, there are no approved therapies that specifically target the metastatic process. Targeting CTCs with novel therapeutics could likely have a significant impact on cancer metastases and patient outcome.”

Among the advantages of the CellBio system are detection from 7.5-mL blood samples with high specificity, sensitivity, and cancer capture rate, complete within 90 minutes. The system applies to cancer screening, diagnosis, monitoring and prognosis; provides optimal treatment; and improves the quality of life for patients. The number of CTCs in the blood can be completely monitored during the non-invasive sampling process, and the capture rate of more than 90 percent of cancer cells is better than the industry norm.

The CellBio FX10, can work with 10 samples at a time with a full-color touch screen, while CellBio a2000 can detect 2 samples at a time in small-space labs. GBC has already accumulated more than 8,000 samples, resulting in good efficacy. According to BBC research, the global liquid biopsy market for cancer applications was US$1.7 billion in 2020 and is expected to grow at a compound annual growth rate of 50.7 percent, reaching a forecasted size of US$13.6 billion by 2025. Major market segments include bladder, breast, colon, gynecology-related cancers, lung cancer, pan-cancer and prostate cancer.

In addition to CTC systems, GBC introduces the Samples-To-Results automated All-in-One molecular system, GB RealQuant® AIO. The system consolidates extraction, amplification and detection in one easy-to-use integrated instrument, providing fast and reliable results within 2 hours with high flexibility. The system works with all GB RealQuant HBV, HCV, and HPV Kits.

For more information about GBC, visit www.gbc.com.tw

 

Media contacts

Frank Lin, GBC President, (03)577-9221, frank.lin@gbc.com.tw

TAIPEI, Taiwan, Aug. 19, 2022 — General Biologicals Corporation (GBC), a Taiwanese In-Vitro Diagnostic (IVD) specializing in Precision Diagnostics was honored with the “2022 HR Asia Best Companies to Work for in Asia”. 

In all, 26,200 employees from 330 Taiwanese companies took part in HR Asia’s proprietary Total Engagement Assessment Model – ranking their own employers on metrics ranging from workplace happiness and team cohesion to employee advocacy and continued job motivation. The top 97 companies who made the cut off point this year are then named HR Asia Best Companies to work for in Asia 2022 for the Taiwanese market.

“HR Asia Best Companies to Work for in Asia is the only award that is judged solely by the nominees’ employees – making this the most transparent award of its kind. Equally important, with 15 markets, and over 400,000 surveys done each year – the program is also the most extensive awards for employee engagement and workplace excellence across the region”, says William Ng, group publisher of Business Media International, the owner of HR Asia.

Mr. Frank Lin, President of GBC, said that the group believes that talents are the cornerstone of the sustainable development of the enterprise. Since its establishment, it has adhered to the value-oriented development of all colleagues and the group, including various company benefits, focusing on the physical and mental health of colleagues, respecting the positions of colleagues in various departments, and maintaining colleagues at any time. Coordinating communication and feedback and encouraging the provision of resources for professional training of talents, etc., this award affirms the Group’s progress towards a happy enterprise and sustainable development goals.

 

About General Biologicals Corporation

Founded in 1984, General Biologicals Corporation (GBC) is a developer and manufacturer of diagnostics and pharmaceutical products headquartered in Taiwan. GBC develops high-quality in-vitro diagnostics for doctors to make clinical decisions in the areas of hepatitis, tumor markers, retrovirus, fertility, thyroid, and steroids. The company also provides anti-bacterial peptides (US FDA Clinical Trial Phase IIb) in the areas of pharmaceutical, cosmetics, and oral products.